^(125)I粒子植入及动脉灌注吉西他滨+奥沙利铂治疗肝癌TACE术后残存病灶的临床研究  

作　　者：伦俊杰 孙建业 殷好治 胡效坤[2] 

机构地区：[1]山东省昌乐县人民医院肿瘤科,山东262400 [2]青岛大学附属医院介入医学中心,266011

出　　处：《当代医学》2014年第24期6-8,共3页Contemporary Medicine

摘　　要：目的探讨125I放射性粒子植入及肝动脉灌注化疗治疗肝癌TACE术后残存病灶的临床价值。方法选取2008年1月~2012年1月总共63例肝癌行TACE治疗后残留病灶的患者纳入研究。随机分成2组:33例行125I放射性粒子植入治疗,为A组,30例行肝动脉灌注吉西他滨+奥沙利铂治疗,为B组。分别评价2组患者的临床疗效及毒副反应。结果 125I放射性粒子植入治疗33例患者,总有效率81.8%(27/33),中位生存期18.5个月。肝动脉灌注吉西他滨+奥沙利铂治疗30例,总有效率44.33%(13/30),中位生存期13个月。125I放射性粒子植入组有效率及中位生存期明显高于吉西他滨+奥沙利铂组,差异有统计学意义(P<0.05)。结论 125I放射性粒子植入治疗肝癌TACE术后残存病灶是一种安全、有效的治疗方法。Objective To evaluate the clinical efficacy of125I seeds implantation and transarterial infusion in the treatment of residual hepatocellular carcinoma after transcatheter arterial chemocebolization.Methods From January 2008 to January 2012. Retrospectively analyzed clinical datas of 63 patients were randomly divided into two groups. 33 cases were treated with125I seeds （group A）, 30 cases were treated with gemcitabine and oxaliplatin （group B）. The efficacy and toxicity in the two groups were evaluated.Results In125I seeds group the total effcetive rate was 81.8%（27/33）,the median survival times was 18.5 months. In gemcitabine and oxaliplatin group the total effcetive rate was 43.33%（13/30）, the median survival times was 13 months. The total effcetive rate and median survival in125I seeds group were significantly higher and longer than those in gemcitabine and oxaliplatin group （P〈0.05）.Conclusion It is safe and effective that radioactive seeds125I was used for implantation in treating residual hepatocellular carcinoma after TACE.

关 键 词：肝癌 残存病灶 碘放射性核素 吉西他滨 奥沙利铂 

分 类 号：R735.7[医药卫生—肿瘤]